Gerresheimer AG (GRRMF) Stock Analysis

Gerresheimer AG (GRRMF) Healthcare & Pipeline Overview

Gerresheimer AG manufactures specialized packaging solutions and drug delivery systems for the healthcare industry, focusing on plastics, glass, and advanced technologies. With a global presence and a history dating back to 1864, the company serves pharmaceutical, biotech, and cosmetic sectors with a diverse product portfolio.

What Is the Investment Thesis for GRRMF?

Gerresheimer AG presents an investment opportunity within the healthcare sector, driven by its diverse product portfolio and global presence. The company's focus on drug delivery systems and specialized packaging caters to the growing demand for advanced healthcare solutions. With a market capitalization of $1.11B and a P/E ratio of 26.14, Gerresheimer exhibits a moderate valuation. Key growth catalysts include the expansion of its Advanced Technologies division and increasing demand for injectable drugs. However, investors may want to evaluate the company's relatively low profit margin of 1.0% and potential risks associated with regulatory changes and competition. The dividend yield is 0.23%.

Based on FMP financials and quantitative analysis

GRRMF Key Highlights

Market capitalization of $1.11B indicates a mid-sized player in the medical instruments and supplies market.

• P/E ratio of 26.14 suggests a moderate valuation compared to its earnings.
• Profit margin of 1.0% reflects a need for improved operational efficiency.
• Gross margin of 26.9% indicates the profitability of its products before operating expenses.
• Dividend yield of 0.23% provides a modest income stream for investors.

Who Are GRRMF's Competitors?

GRRMF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are GRRMF's Key Strengths?

Global presence and established reputation in the healthcare industry.

• Diverse product portfolio spanning packaging, drug delivery systems, and advanced technologies.
• Long-standing relationships with major pharmaceutical companies.
• Expertise in regulatory compliance and quality control.

What Are GRRMF's Weaknesses?

Relatively low profit margin compared to industry peers.

• Dependence on the pharmaceutical industry, making it susceptible to regulatory changes.
• Limited brand recognition among consumers.
• Exposure to currency fluctuations due to its global operations.

What Could Drive GRRMF Stock Higher?

GRRMF catalyst: Expansion of the Advanced Technologies division with new product launches in micro pumps and smart drug delivery systems.

• Increasing demand for injectable drugs driving growth in the Plastics & Devices division.
• Strategic partnerships and acquisitions to expand product portfolio and market reach.
• Potential regulatory approvals for new drug delivery devices in key markets.
• Focus on sustainable packaging solutions attracting environmentally conscious customers.

What Are the Key Risks for GRRMF?

Financial-distress signal — its Altman Z-Score of 0.98 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-23.6%) — the business is not currently generating profit on shareholder capital.
• Inconsistent delivery — missed Wall Street EPS estimates in 3 of the last 8 reported quarters.
• Intense competition from established players and new entrants in the healthcare packaging market.
• Stringent regulatory requirements and potential product recalls affecting product sales and reputation.
• Economic downturns affecting healthcare spending and demand for pharmaceutical products.
• Exposure to currency fluctuations due to its global operations.
• Relatively low profit margin compared to industry peers, requiring improved operational efficiency.

What Are the Growth Opportunities for GRRMF?

• Expansion of Advanced Technologies Division: Gerresheimer's Advanced Technologies division, which develops smart drug delivery systems like micro pumps, represents a significant growth opportunity. The market for advanced drug delivery systems is projected to reach $24.7 billion by 2027, driven by the increasing demand for personalized medicine and self-administration options. By focusing on innovative solutions for chronic diseases like Parkinson's and heart failure, Gerresheimer can capture a larger share of this expanding market. Timeline: Ongoing.
• Increasing Demand for Injectable Drugs: The rising prevalence of chronic diseases and the growing biologics market are driving increased demand for injectable drugs, creating a significant opportunity for Gerresheimer's Plastics & Devices division. The global injectable drug market is expected to reach $790.7 billion by 2030. Gerresheimer's expertise in manufacturing prefillable syringes and other injectable drug delivery systems positions it well to capitalize on this trend. Timeline: Ongoing.
• Growth in Emerging Markets: Emerging markets, with their rapidly growing populations and increasing healthcare expenditure, present a substantial growth opportunity for Gerresheimer. These markets are experiencing a rising demand for pharmaceutical packaging and drug delivery systems. By expanding its presence in regions like Asia-Pacific and Latin America, Gerresheimer can tap into new revenue streams and diversify its geographic footprint. Timeline: Ongoing.
• Strategic Partnerships and Acquisitions: Gerresheimer can pursue strategic partnerships and acquisitions to expand its product portfolio, enhance its technological capabilities, and strengthen its market position. Collaborating with pharmaceutical companies and biotech firms can facilitate the development of innovative drug delivery solutions and secure long-term supply contracts. Acquisitions of complementary businesses can provide access to new markets and technologies. Timeline: Ongoing.
• Focus on Sustainable Packaging Solutions: With increasing environmental awareness, there is a growing demand for sustainable packaging solutions in the healthcare industry. Gerresheimer can capitalize on this trend by developing and offering eco-friendly packaging options, such as recyclable plastics and bio-based materials. By positioning itself as a leader in sustainable packaging, Gerresheimer can attract environmentally conscious customers and gain a competitive advantage. Timeline: Ongoing.

What Are GRRMF's Competitive Advantages?

• Specialized Expertise: Gerresheimer's deep expertise in manufacturing specialized packaging and drug delivery systems creates a barrier to entry for new competitors.
• Long-Term Relationships: The company's long-standing relationships with pharmaceutical companies and biotech firms provide a stable revenue stream and a competitive advantage.
• Regulatory Compliance: Gerresheimer's adherence to stringent regulatory requirements in the healthcare industry ensures product quality and safety, building trust with customers.
• Global Footprint: The company's global manufacturing and distribution network allows it to serve customers in both established and emerging markets.

What Does GRRMF Do?

Founded in 1864 and headquartered in Düsseldorf, Germany, Gerresheimer AG has evolved into a leading global manufacturer of packaging products and drug delivery devices. The company operates through three primary divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The Plastics & Devices division offers a range of drug delivery systems, including inhalers, insulin pen systems, and prefillable syringes, along with diagnostic systems for the pharma, biotech, diagnostics, and medical technology industries. This division also provides containers and closures, PET bottles, eye droppers, nasal sprays, nebulizers, applicators, and accessories for solid, liquid, and ophthalmic applications, as well as bottles and containers for nutritional supplements. The Primary Packaging Glass division focuses on glass primary packaging for the pharma and cosmetics industries, producing infusion, dropper, and syrup bottles, injection vials, ampoules, and cartridges. Additionally, it offers miniature bottles and glass containers for liquid food, spices, and spirits, along with packaging solutions for fragrances, deodorants, skin care, and wellness products, as well as beauty and pharmaceutical products. The Advanced Technologies division is dedicated to developing smart drug delivery systems, such as micro pumps, which are used to self-administer medication for conditions like Parkinson's disease or heart failure. Gerresheimer serves a diverse customer base across the pharmaceutical, biotech, diagnostics, medical technology, and cosmetics industries, with a global footprint that allows it to cater to both established and emerging markets.

What Products and Services Does GRRMF Offer?

• Manufactures plastic containers and closures for liquid and solid pharmaceuticals.
• Produces glass vials, ampoules, and cartridges for injectable drugs.
• Develops and manufactures drug delivery systems, including inhalers and pen systems.
• Offers packaging solutions for the cosmetics and personal care industries.
• Creates advanced micro pumps for self-administration of medication.
• Provides diagnostic systems for the pharma and biotech sectors.

How Does GRRMF Make Money?

• Manufacturing and selling primary packaging glass for pharmaceutical and cosmetic products.
• Producing plastic containers and drug delivery systems for the healthcare industry.
• Developing and commercializing advanced drug delivery technologies.
• Generating revenue through long-term supply contracts with pharmaceutical companies.

What Industry Does GRRMF Operate In?

Gerresheimer AG operates in the medical instruments and supplies industry, which is characterized by continuous innovation and stringent regulatory requirements. The market is driven by increasing healthcare expenditure, an aging population, and the rising prevalence of chronic diseases. The competitive landscape includes companies like BOEUF, EBOSY, EKTAF, EKTAY, and GENSF, each vying for market share through product differentiation and strategic partnerships. Trends such as personalized medicine and the growing demand for self-administered drug delivery systems are shaping the industry's future.

Who Are GRRMF's Key Customers?

• Pharmaceutical companies requiring primary packaging for drugs.
• Biotech firms needing drug delivery systems for injectable medications.
• Cosmetics companies seeking packaging solutions for beauty products.
• Healthcare providers using diagnostic systems and drug delivery devices.

Wall Street analysts project Gerresheimer AG revenue of about $2.36B for fiscal 2026, with EPS near $1.83. The estimate reflects 12 contributing analysts.

Gerresheimer AG has missed Wall Street's EPS estimate in 3 of its last 8 reported quarters — a mixed record worth weighing.

Gerresheimer AG's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 0.98 places it in the distress zone, a signal of elevated financial risk.

Return on equity for Gerresheimer AG stands at -23.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -7.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -11.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.81 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -36.1%, the inverse of the P/E and a quick read on earnings relative to price.

Gerresheimer AG (GRRMF) Valuation Context

Valued at $1.11B, GRRMF is classified as a small-cap stock.

GRRMF Revenue & Earnings Trend

In Q4 FY2025, GRRMF generated $742.0M in top-line revenue, marking a sequential increase of 14.1%. The company recorded a net loss of $355.8M, with diluted EPS of $-10.30. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, GRRMF averaged $-2.69 in diluted EPS.

Company Profile

Gerresheimer AG operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Düsseldorf, DE. The company is led by CEO Uwe Ferdinand Röhrhoff. GRRMF has traded publicly since 2009.

GRRMF Financials

GRRMF Latest News

GRRMF Analyst Consensus

GRRMF MoonshotScore

GRRMF Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources